Late-stage lung cancer patients with non-small cell lung cancers who demonstrate high levels of PDL1 expression have better outcomes when placed on a combined treatment program of both immunotherapy and chemotherapy. There is a subset of patients that respond well to pembrolizumab, an immunotherapy drug, alone as an initial treatment path, but there are no […]
Read More